Tuesday Apr 15
Eisai CEO Haruo Naito Appointed Knight Commander of British Empire
Tokyo, Apr 15, 2014 - - Eisai Co., Ltd. announced today that in recognition of his valuable contribution to relations between Britain and Japan, Her Majesty Queen Elizabeth II has appointed Dr. Haruo Naito, President & CEO of Eisai Co., Ltd. to be an Honorary Knight Commander of the Order of the British Empire .
Trending on the Topix Network
Mon Apr 14, 2014
Customer Interaction Solutions
Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director
Receptos, Inc. , a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Lynne Hedley, Ph.D. as a director of Receptos.
Fri Apr 11, 2014
Mon Apr 07, 2014
Eisai Launches New Energy Drink 'Joma'
"Cast a Spell of Happiness" Tokyo, Apr 7, 2014 - - Eisai Co., Ltd. announced that it launched its new energy drink, Joma, in Japan today, April 7. With the slogan "Cast a spell of happiness", Joma is an energy drink designed to conjure up the image ofa witch, whose powers transcend human abilities.
Mon Mar 31, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
ETS2101 well tolerated with no serious adverse events. Early evidence of possible hal...
Eisai Assigns Its Worldwide Exclusive License for DACOGENA to Otsuka
We give our first thoughts to patients and their families, and helping to increase the benefits health care provides.
Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen from Eisai
Otsuka has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen A .
Tue Mar 25, 2014
Notice Concerning Voluntary Adoption of International Financial Reporting Standards
Tokyo, Mar 25, 2014 - - Eisai Co., Ltd. announced today that, at a meeting of its Board of Directors held earlier today, it resolved to voluntarily adopt International Financial Reporting Standards for consolidated financial statements in lieu of the Japanese Generally Accepted Accounting Principles it has currently adopted.
Fri Mar 21, 2014
Eisai Partners With Liverpool Institutions To Develop Drugs
Eisai Co., Ltd. announced it has entered into collaboration with two Liverpool educational institutions to identify and develop drugs for anti-wolbachia therapy against filariasis.
Wed Mar 19, 2014
Eisai Enters Collaboration with Liverpool School of Tropical Medicine ...
Joint Research Project Awarded Ghit Fund Grant Tokyo, Mar 20, 2014 - - Eisai Co., Ltd. announced today that it has entered a collaboration with the Liverpool School of Tropical Medicine and University of Liverpool to jointly identify new drugs effective against lymphatic filariasis and onchocerciasis , both major types of filariasis.